84 results about "Optic neuropathy" patented technology

Methods for analyzing retinal tomography maps to detect patterns of optic nerve diseases such as glaucoma, optic neuritis, anterior ischemic optic neuropathy are disclosed in this invention. The areas of mapping include the macula centered on the fovea, and the region centered on the optic nerve head. The retinal layers that are analyzed include the nerve fiber, ganglion cell, inner plexiform and inner nuclear layers and their combinations. The overall retinal thickness can also be analyzed. Pattern analysis are applied to the maps to create single parameter for diagnosis and progression analysis of glaucoma and optic neuropathy.

Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating glaucomatous retinopathy or optic neuropathy. The structurally diverse agents that act on the Nrf2 / ARE pathway induce the expression of enzymes and proteins that possess chemically versatile cytoprotective properties and are a defense against toxic metabolites and xenobiotics. Agents include certain electrophiles and oxidants such as a Michael Addition acceptor, diphenol, thiocarbamate, quinone, 1,2-dithiole-3-thione, butylated hydroxyanisole, flavonoid, an isothiocyanate, 3,5-di-tert-butyl-4-hydroxytoluene, ethoxyquin, a coumarin, combinations thereof, or a pharmacologically active derivative or analog thereof.

Based on optical coherence tomography (OCT) imaging of a portion of an eye, a mask of an anatomical feature is derived. Using the mask as a reference, a scan path is determined that is at least partially fitted to and / or partially enclosing the mask. OCT scan data corresponding to the scan path is acquired and analyzed to detect optic neuropathies.

A use method of agmatine or a pharmaceutically allowable salt thereof, and a pharmaceutical composition comprising the same are disclosed. The method and pharmaceutical composition of the present invention can effectively cure or prevent eye diseases preferably including glaucoma, retinopathy, and optic neuropathy associated with apoptosis in retinal ganglion cells (RGCs), particularly hypoxia-induced or tumor necrosis factor-α (TNF-α)-induced apoptosis.

The invention discloses a medicament for improving eyesight. In the medicament, szechuan tangshen root, astragalus, large-headed atractylodes, Chinese angelica, rehmanniae vaporata, red paneoy root, rehmanniae praeparatum, gardenia fruit, medlar, eucommia bark, south dodder seed, raspberry, root of red-rooted salvia, notoginseng root, pale butterflybush flower, blackend swallowwort root, fish poison yarn and chrysanthemum are ground into 200-mesh powder, and are mixed uniformly, sterilized and packaged, wherein each bag contains 5 grams of medicament. The medicament is mainly used for treating patients who suffer from blurred vision caused by symptoms such as deficiency in kidney and yang, deficiency in blood and qi, diabetes mellitus, retinopathy, fundus hemorrhage, vitreous opacity, glaucoma or optic nerve pathological changes and the like, and 50 patients who suffer from the blurred vision are selected in the outpatient service of a hospital randomly to take the medicament. In the administration method and dosage, adults take twice every day, and takes 5 grams every time; for the children, the dosage is reduced by half; and 20 days is one treatment course, the total cure rate is 69 percent, the total cure rate of two treatment courses is 86.3, and the cure rate of three treatment course is 97.2 percent.

An apparatus and a method for diagnosing optic neuropathic diseases including glaucoma, are provided. The apparatus for diagnosing optical neuropathic diseases measures a thickness of a retinal nerve fiber layer (RNFL) using methods such as optical coherence tomography (OCT) and scanning laser polarimetry, and includes a scanning unit which scans along an optic nerve margin in the proximity of an optic nerve head, a pattern analyzing unit which analyzes a pattern of the RNFL scanned by the scanning unit, and a disease determining unit which determines a presence of the disease based on the pattern of the RNFL analyzed by the pattern analyzing unit.